Polyrizon's Stock Soars on Manufacturing Milestone, Reverse Split & $17M Raise
Introduction
Polyrizon Ltd (NASDAQ: PLRZ) is a development-stage biotechnology company headquartered in Ra’anana, Israel, specializing in hydrogel-based nasal sprays. Its proprietary Capture and Contain™ (C&C) technology forms a thin, bioadhesive barrier in the nasal cavity to limit the exposure of epithelial tissue to viruses and allergens. The company is also developing a pre-clinical Trap and Target™ (T&T) platform for the intranasal delivery of active pharmaceutical ingredients.
Key Stock Metrics (2025-12-02)
| Ticker | Exchange | Price | Change (%) | Volume |
|---|---|---|---|---|
| PLRZ | NASDAQ | 7.2301 USD | +128.80 | 14,518,958 |
Corporate Structure and Leadership
Founded and led by Tomer Izraeli (B.Sc., MBA), Polyrizon’s executive team includes expertise in pharmaceuticals, medical devices, and organizational consulting. Chief Financial Officer Nir Ben Yosef (CPA, B.A.) has experience from ENvizion Medical Ltd. and a public accounting practice. Daphna Avital (MA) manages human resources, with over 20 years of experience in senior management at Allergan and AstraZeneca. Dr. Tidhar Turgeman oversees technology development, while Yuliya Yutkevich directs regulatory affairs and quality assurance, and Dr. Eyal S. Ron heads scientific strategy. The company is governed by a five-member board and a scientific advisory board comprised of university and clinical experts.
Nasal spray by Diana Polekhina
Recent Developments and News
On December 2, 2025, Polyrizon filed a Form 6-K reporting the completion of a key manufacturing upscaling milestone for its nasal spray platform, indicating progress toward larger-scale production. On November 25, 2025, the company executed a 1-for-6 reverse stock split to maintain NASDAQ compliance, reducing outstanding shares from approximately 6.25 million to approximately 1.04 million. Earlier, on November 7, 2025, Polyrizon filed a Form F-3 registration statement to facilitate future securities offerings. In March 2025, the company announced a $17.0 million private placement with institutional investors at $0.48 per unit. Polyrizon also entered into a manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S. to supply clinical trial material for its PL-14 allergy blocker, with a Phase 1 trial expected in 2025.
Financial and Strategic Analysis
Polyrizon has not yet reported product revenue. Its financings and reverse stock split reflect efforts to secure capital and maintain listing standards. The $17 million private placement in March 2025 is intended to support working capital for operational and research and development programs. Upscaling manufacturing for the C&C hydrogel platform positions the company to support clinical development and potential commercial launch. The F-3 registration statement provides flexibility for future equity offerings, while the reverse stock split aims to enhance share price stability.
Market Position and Industry Context
Polyrizon operates in the niche of intranasal medical devices, targeting requirements in allergy prevention and therapeutic applications. Its hydrogel approach presents a different mechanism compared to traditional drug or vaccine modalities. Competitors in intranasal drug delivery may address similar needs, but few utilize a barrier-forming hydrogel. As a pre-commercial biotech, the company’s value proposition depends on clinical validation of safety, efficacy, and manufacturing scalability in U.S. and European healthcare markets.
tl;dr
— On December 2, 2025, Polyrizon completed a key manufacturing upscaling milestone for its intranasal hydrogel platform.
— A 1-for-6 reverse stock split effective November 28, 2025, reduced shares outstanding to approximately 1.04 million.
— The company secured $17 million in a private placement on March 31, 2025, at $0.48 per unit.
— A manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S. supports material supply for the PL-14 allergy blocker clinical trial scheduled for 2025.
— The Form F-3 registration filed on November 7, 2025, enables future equity offerings to support R&D and commercialization.